The Top 5 Biosimilars Articles for the Week of July 24
The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of July 24, 2017.
Transcript
Hi, I’m Kelly Davio for the Center for Biosimilars, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of July 24.
Number 5: FDA Commissioner, Dr Scott Gottlieb, along with the acting director of the Federal Trade Commission, testified before the House Judiciary Committee on Thursday concerning antitrust issues and the FDA approval process.
Number 4: A recent report on the current pipeline of biopharmaceuticals shows 749 projects under development for diabetes and diabetes-related complications.
Number 3: The House of Representatives passed the Medicare Part B Improvement Act, but the bill could face funding issues after CMS proposed a cut to payment for home healthcare.
Number 2: The prospective adalimumab biosimilar CinnoRA was shown in a recent phase 3 trial to be noninferior to Humira.
And finally, Number 1: This week, Merck announced the US launch of its biosimilar infliximab, Renflexis, at a 35% discount to Remicade.
Read these articles and more at centerforbiosimilars.com.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
